Alcohol use disorders
- PMID: 41077052
- DOI: 10.1016/S0140-6736(25)01496-5
Alcohol use disorders
Abstract
Alcohol use disorders consist of conditions characterised by compulsive heavy alcohol use and loss of control over alcohol intake. Alcohol use disorders are some of the most prevalent mental disorders globally, with higher prevalence in high-income countries and lower prevalence in low-income countries. The recent COVID-19 pandemic was associated with an increase in fully alcohol-attributable mortality, in part triggered by alcohol-specific interactions with stress. Despite their high prevalence, alcohol use disorders remain undertreated, even though there are scientifically established and cost-effective psychosocial, community, and pharmacological interventions available. In addition, promising new treatment modalities have been developed and are currently being tested. The two main barriers to better access to evidence-based alcohol use disorder treatment are low availability, due to the absence of government or public funding for such treatment, and stigma. The first barrier could be overcome by increasing alcohol excise taxation, which currently falls considerably short of covering the social costs of alcohol use. In addition to generating revenues, increasing excise taxation could reduce health-care costs by reducing hospitalisations for all alcohol-attributable conditions, including alcohol use disorders. Overall, integrated alcohol control policies could improve the prevention of alcohol use disorders, improve access to treatment, and reduce stigma.
Copyright © 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
Declaration of interests MN is a staff member of WHO and is alone responsible for the views expressed in this article, and they do not necessarily represent the decisions, policies, or views of WHO. CSH reports grants from public funders, personal consulting fees from Eli Lilly and Apollo Therapeutics; remuneration for being on the Advisory Board of Apollo Therapeutics; and remuneration for serving on a Data Safety Monitoring Board by the National Institute on Drug Abuse. JR, SA, AF, MN, ASH, and KDS report no competing interests.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
